ALK and neoplasm: Ceritinib inhibits not only ALK but also secondary mutations of ALK, including L1196M, G1269A, S1206Y, and I1171T EML4-ALK mutants [171], and IGF1R, which plays a significant role in tumor growth and is overexpressed in several CNS metastases [170, 172, 173].